Cargando…
Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Considering the increasing importance of immune checkpoints in tumor immunity we investigated the clinical relevance of serum T-cell immunoglobulin and mucin domain-3 (TIM-3) in patients with hepatocellular carcinoma (HCC). Serum TIM-3 levels were measured and their association with HCC stage and th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016746/ https://www.ncbi.nlm.nih.gov/pubmed/31952209 http://dx.doi.org/10.3390/cancers12010212 |
_version_ | 1783497046055976960 |
---|---|
author | Tampaki, Maria Ionas, Evangelos Hadziyannis, Emilia Deutsch, Melanie Malagari, Katerina Koskinas, John |
author_facet | Tampaki, Maria Ionas, Evangelos Hadziyannis, Emilia Deutsch, Melanie Malagari, Katerina Koskinas, John |
author_sort | Tampaki, Maria |
collection | PubMed |
description | Considering the increasing importance of immune checkpoints in tumor immunity we investigated the clinical relevance of serum T-cell immunoglobulin and mucin domain-3 (TIM-3) in patients with hepatocellular carcinoma (HCC). Serum TIM-3 levels were measured and their association with HCC stage and the detection of serum programmed death ligand-1 (PD-L1) were assessed. In patients submitted to transarterial chemoembolization (TACE), pre- and 1-week post-treatment TIM-3 levels were also evaluated. We studied 53 HCC patients with BCLC stages: 0 (5.7%), A (34%), B (32.1%), C (22.6%), and D (5.7%). The patients with advanced HCC (BCLC C) had significantly higher TIM-3 levels than patients with BCLC A (p = 0.009) and BCLC B (p = 0.019). TIM-3 levels were not associated with HCC etiology (p = 0.183). PD-L1 detection (9/53 patients) correlated with TIM-3 levels (univariate analysis, p = 0.047). In 33 patients who underwent TACE, post-treatment TIM-3 levels (231 pg/mL, 132–452) were significantly higher than pre-TACE levels (176 pg/mL, 110–379), (p = 0.036). Complete responders had higher post-TACE TIM-3 levels (534 pg/mL, 370–677) than partial responders (222 pg/mL, 131–368), (p = 0.028). Collectively, TIM-3 may have a role in anti-tumor immunity following TACE, setting a basis for combining immunotherapy and chemoembolization. |
format | Online Article Text |
id | pubmed-7016746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70167462020-02-28 Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Tampaki, Maria Ionas, Evangelos Hadziyannis, Emilia Deutsch, Melanie Malagari, Katerina Koskinas, John Cancers (Basel) Article Considering the increasing importance of immune checkpoints in tumor immunity we investigated the clinical relevance of serum T-cell immunoglobulin and mucin domain-3 (TIM-3) in patients with hepatocellular carcinoma (HCC). Serum TIM-3 levels were measured and their association with HCC stage and the detection of serum programmed death ligand-1 (PD-L1) were assessed. In patients submitted to transarterial chemoembolization (TACE), pre- and 1-week post-treatment TIM-3 levels were also evaluated. We studied 53 HCC patients with BCLC stages: 0 (5.7%), A (34%), B (32.1%), C (22.6%), and D (5.7%). The patients with advanced HCC (BCLC C) had significantly higher TIM-3 levels than patients with BCLC A (p = 0.009) and BCLC B (p = 0.019). TIM-3 levels were not associated with HCC etiology (p = 0.183). PD-L1 detection (9/53 patients) correlated with TIM-3 levels (univariate analysis, p = 0.047). In 33 patients who underwent TACE, post-treatment TIM-3 levels (231 pg/mL, 132–452) were significantly higher than pre-TACE levels (176 pg/mL, 110–379), (p = 0.036). Complete responders had higher post-TACE TIM-3 levels (534 pg/mL, 370–677) than partial responders (222 pg/mL, 131–368), (p = 0.028). Collectively, TIM-3 may have a role in anti-tumor immunity following TACE, setting a basis for combining immunotherapy and chemoembolization. MDPI 2020-01-15 /pmc/articles/PMC7016746/ /pubmed/31952209 http://dx.doi.org/10.3390/cancers12010212 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tampaki, Maria Ionas, Evangelos Hadziyannis, Emilia Deutsch, Melanie Malagari, Katerina Koskinas, John Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma |
title | Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma |
title_full | Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma |
title_fullStr | Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma |
title_full_unstemmed | Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma |
title_short | Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma |
title_sort | association of tim-3 with bclc stage, serum pd-l1 detection, and response to transarterial chemoembolization in patients with hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016746/ https://www.ncbi.nlm.nih.gov/pubmed/31952209 http://dx.doi.org/10.3390/cancers12010212 |
work_keys_str_mv | AT tampakimaria associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma AT ionasevangelos associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma AT hadziyannisemilia associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma AT deutschmelanie associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma AT malagarikaterina associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma AT koskinasjohn associationoftim3withbclcstageserumpdl1detectionandresponsetotransarterialchemoembolizationinpatientswithhepatocellularcarcinoma |